These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Kinsella MG; Tran PK; Weiser-Evans MC; Reidy M; Majack RA; Wight TN Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):608-14. PubMed ID: 12615671 [TBL] [Abstract][Full Text] [Related]
6. Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury. Gotha L; Lim SY; Osherov AB; Wolff R; Qiang B; Erlich I; Nili N; Pillarisetti S; Chang YT; Tran PK; Tryggvason K; Hedin U; Tran-Lundmark K; Advani SL; Gilbert RE; Strauss BH Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H337-45. PubMed ID: 24858854 [TBL] [Abstract][Full Text] [Related]
7. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Zhou Z; Wang J; Cao R; Morita H; Soininen R; Chan KM; Liu B; Cao Y; Tryggvason K Cancer Res; 2004 Jul; 64(14):4699-702. PubMed ID: 15256433 [TBL] [Abstract][Full Text] [Related]
8. p27 Nuclear localization and growth arrest caused by perlecan knockdown in human endothelial cells. Sakai K; Oka K; Matsumoto K; Nakamura T Biochem Biophys Res Commun; 2010 Feb; 392(3):403-8. PubMed ID: 20074558 [TBL] [Abstract][Full Text] [Related]
9. Endothelial heparan sulfate is necessary but not sufficient for control of vascular smooth muscle cell growth. Ettenson DS; Koo EW; Januzzi JL; Edelman ER J Cell Physiol; 2000 Jul; 184(1):93-100. PubMed ID: 10825238 [TBL] [Abstract][Full Text] [Related]
10. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Nugent MA; Nugent HM; Iozzo RV; Sanchack K; Edelman ER Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6722-7. PubMed ID: 10841569 [TBL] [Abstract][Full Text] [Related]
11. Essential contribution of tumor-derived perlecan to epidermal tumor growth and angiogenesis. Jiang X; Multhaupt H; Chan E; Schaefer L; Schaefer RM; Couchman JR J Histochem Cytochem; 2004 Dec; 52(12):1575-90. PubMed ID: 15557212 [TBL] [Abstract][Full Text] [Related]
12. The role of smooth muscle derived tissue factor in mediating thrombosis and arterial injury. Taubman MB; Wang L; Miller C Thromb Res; 2008; 122 Suppl 1():S78-81. PubMed ID: 18691507 [TBL] [Abstract][Full Text] [Related]
13. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129 [TBL] [Abstract][Full Text] [Related]
14. [Progress in angiogenesis regulation of perlecan]. Liu XH Sheng Li Ke Xue Jin Zhan; 2006 Jan; 37(1):48-50. PubMed ID: 16683546 [No Abstract] [Full Text] [Related]
15. The modulation of platelet and endothelial cell adhesion to vascular graft materials by perlecan. Lord MS; Yu W; Cheng B; Simmons A; Poole-Warren L; Whitelock JM Biomaterials; 2009 Oct; 30(28):4898-906. PubMed ID: 19540587 [TBL] [Abstract][Full Text] [Related]
16. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Camozzi M; Zacchigna S; Rusnati M; Coltrini D; Ramirez-Correa G; Bottazzi B; Mantovani A; Giacca M; Presta M Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1837-42. PubMed ID: 16020751 [TBL] [Abstract][Full Text] [Related]
17. Perlecan Heparan Sulfate Is Required for the Inhibition of Smooth Muscle Cell Proliferation by All-trans-Retinoic Acid. Tran-Lundmark K; Tannenberg P; Rauch BH; Ekstrand J; Tran PK; Hedin U; Kinsella MG J Cell Physiol; 2015 Feb; 230(2):482-7. PubMed ID: 25078760 [TBL] [Abstract][Full Text] [Related]